IDEXX Laboratories, Inc. — Fiscal 2017 Form 10-K Summary
Business context and reporting period
IDEXX develops and sells diagnostic products and services for companion-animal veterinary, water-quality, livestock, poultry and dairy markets, with a smaller human point-of-care diagnostics business. The filing covers the fiscal year ended December 31, 2017; quarterly data includes the three months ended December 31, 2017. Approximately 39% of annual revenue came from customers outside the United States.
Key financial metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $1,969.1 million | $1,775.4 million | +10.9% |
| Gross profit | $1,097.4 million | $975.4 million | +12.5% |
| Gross margin | 55.7% | 54.9% | +80 bps |
| Operating income | $413.0 million | $350.2 million | +17.9% |
| Operating margin | 21.0% | 19.7% | +130 bps |
| Net income attributable to IDEXX stockholders | $263.1 million | $222.0 million | +18.5% |
| Diluted EPS | $2.94 | $2.44 | +20.5% |
| Operating cash flow | $373.3 million | $338.9 million | +10.1% |
| Capital expenditures | $74.4 million | $64.8 million | +14.8% |
Cash, cash equivalents and marketable securities totaled $471.9 million at year-end, compared with $391.8 million in 2016. Working capital was negative $32.6 million. Debt consisted of $655.0 million outstanding under the revolving credit facility and $606.1 million of long-term debt. Gross debt was $1.266 billion, net debt was $793.6 million, and net debt to adjusted EBITDA was 1.51x. The company had $194.0 million of remaining borrowing availability under its $850 million credit facility and was in compliance with debt covenants.
Recurring CAG diagnostic revenue represented approximately 74% of consolidated revenue. CAG revenue increased 11.9% to $1.703 billion, driven by reference laboratory services, VetLab consumables and rapid assay products. Water revenue increased 10.4% to $114.4 million. LPD revenue increased 1.6% to $128.5 million, while LPD operating income declined 13.0% to $16.5 million.
Material changes versus the prior comparable period
- Growth was led by CAG Diagnostics recurring revenue, which increased 13.3% to $1.452 billion. Reference laboratory revenue increased 13.6%, and VetLab consumables increased 14.9%.
- Gross-margin expansion reflected price increases, lower product and manufacturing costs, and favorable mix toward recurring diagnostic revenue, partly offset by currency and laboratory-capacity investments.
- CAG operating margin improved to 21.3% from 19.8%, while LPD operating margin declined to 12.8% from 15.0% because of higher product costs and weaker dairy and herd-health demand.
- Other operating income increased to $4.8 million from $0.9 million, principally because 2016 included a $2.2 million non-cash OPTI Medical intangible-asset impairment and related development reductions.
- The company acquired a reference laboratory in Austria, four U.S. reference-laboratory customer lists and two software businesses, including rVetLink-related referral-management capabilities. Acquisition-related investing cash outflows totaled $14.6 million.
- Share repurchases declined to 1.749 million shares costing $270.3 million, versus 3.071 million shares costing $313.1 million in 2016. Approximately 5.0 million shares remained authorized for repurchase at year-end. No cash dividends were declared or paid.
- Adoption of ASU 2016-09 produced approximately $27.7 million of income-tax benefit from share-based payment settlements and increased operating cash flow by the same amount relative to prior classification.
Guidance, outlook, commentary, risks and unusual items
- Management projected a 2018 effective tax rate of 20% to 21%, reflecting the Tax Cuts and Jobs Act. The 2017 results included a provisional $48.8 million deemed-repatriation tax liability, payable over eight years, partially offset by approximately $17 million from remeasurement of deferred tax liabilities.
- The company estimated 2018 capital expenditures of approximately $140 million for headquarters expansion, German laboratory relocation and expansion, manufacturing and laboratory equipment, software, information technology and facilities.
- Management expected adoption of the new revenue standard in the first quarter of 2018 on a modified-retrospective basis. The company estimated a net 2018 revenue increase of approximately $10 million from adoption and anticipated a retained-earnings charge of less than $10 million at adoption.
- Revenue recognition will shift among instrument placements, recurring consumables and other services under customer commitment and rebate programs. The filing states that the change affects timing rather than the underlying economics of these arrangements.
- Management believes available cash, marketable securities, operating cash flow and committed borrowing capacity are sufficient for operations, capital requirements and anticipated growth for at least the next twelve months.
- Primary risks include intense competition and customer consolidation, reliance on sole or single-source suppliers, regulatory approvals, foreign-currency volatility, cybersecurity and data-privacy exposure, economic sensitivity in veterinary and testing markets, tax audits and evolving tax rules, debt covenant compliance, and potential product or patent litigation.
- Foreign-exchange sensitivity was material: a 1% strengthening of the U.S. dollar was estimated to reduce 2018 revenue by approximately $8 million and operating income by approximately $4 million, partly offset by approximately $2 million of hedge gains.
- No goodwill or intangible-asset impairment was recorded in 2017. Pending ordinary-course legal matters were not expected by management to have a material effect, although unfavorable outcomes could materially affect a particular period.
Most important facts for investors to verify
- Whether recurring CAG diagnostic growth, installed-base expansion and consumables utilization continue to support revenue and margin expansion.
- The effect of the 2018 revenue-standard adoption on reported revenue mix, deferred revenue, retained earnings and segment margins.
- The realized 2018 tax rate and cash-tax payments following the Tax Act and the $48.8 million repatriation-tax liability.
- Execution and funding of the approximately $140 million 2018 capital-expenditure plan, including the intended liquidation of marketable securities and partial repayment of the credit facility.
- Debt levels, variable-rate exposure and compliance with the 3.5-to-1 leverage covenant.
- Supplier continuity for Catalyst, ProCyte, SediVue, VetTest and other products dependent on sole or single-source vendors.
- Progress integrating the 2017 software and laboratory acquisitions and the impact of international expansion, foreign exchange and regulatory developments.